Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT05220878
Other study ID # RMP-ITP-III
Secondary ID ? 407 eff. date
Status Completed
Phase Phase 3
First received
Last updated
Start date September 9, 2021
Est. completion date October 19, 2023

Study information

Verified date March 2024
Source AO GENERIUM
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

It is a phase III multicenter randomized double-blinded comparative study of clinical efficacy and safety of GNR-069 and Nplate in patients with idiopathic thrombocytopenic purpura


Description:

The drug GNR-069(JSC "GENERIUM", Russia) is biosimilar to the original drug Nplate. This study is aimed to compare the clinical efficacy and safety of the drug GNR-069 and the drug Nplate to register of the drug GNR-069 in the Russian Federation for therapy in patients with idiopathic thrombocytopenic purpura (ITP). The study also provides for the evaluation of pharmacokinetic parameters and immunogenicity.


Recruitment information / eligibility

Status Completed
Enrollment 160
Est. completion date October 19, 2023
Est. primary completion date August 22, 2023
Accepts healthy volunteers No
Gender All
Age group 18 Years to 75 Years
Eligibility Inclusion Criteria: 1. Written Informed Consent Form to participate in the study; 2. Men and women aged 18-75 years inclusive at the time of signing the Informed Consent Form; 3. Documented diagnosis of ITP with a disease duration of more than 12 months from the moment of confirmation of the diagnosis by bone marrow aspirate or biopsy results; 4. A. For patients who have not had splenectomy: - established absence/loss of response to therapy with at least one drug of fist-line treatment for ITP (which include GCs an IVIG); OR - the occurrence of side effects during the course of therapy with the drug of the fist-line, making it impossible to use it further; B. For patients who underwent splenectomy: • loss/lack of response to splenectomy; 5. Thrombocytopenia =30.0 x 109/L - <50.0 x 109/L with severe hemorrhagic syndrome or thrombocytopenia <30.0 x 109/l, regardless of the presence of hemorrhagic syndrome, according to the results of platelet count conducted in a local laboratory for 7 days before the start of therapy with investigational or reference drug; 6. Patients receiving GCs, azathioprine and danazole should receive these drugs in a maintenance dose for at least 4 weeks before starting therapy with investigational or reference drug; 7. Consent of study participants with preserved childbearing function to use reliable methods of contraception (a combination of at least two methods, including 1 barrier method, for example, the use of a condom and spermicide) from the moment of signing the Informed Consent Form and 3 months after the last administration of investigational or reference drug. Exclusion Criteria: 1. Hypersensitivity to the components of investigational or reference drug or E. coli proteins ; 2. Unresolved severe hemorrhagic syndrome requiring emergency treatment at the time of initiation of study or reference drug therapy ; 3. Fisher-Evans Syndrome; 4. Conditions with a high risk of thromboembolic complications ; 5. Myelodysplastic syndrome and/or bone marrow transplantation in anamnesis; 6. Deviations of clinical and laboratory parameters according to the results of studies of blood samples taken during the screening period; 7. Positive test results for hepatitis B, hepatitis C, or human immunodeficiency virus (HIV); 8. Pregnancy or breastfeeding; 9. Use of drugs: - romiplostim used less than 3 weeks before treatment with study or reference drug; - IVIG - less than 2 weeks prior to initiation of study or reference drug therapy; - eltrombopag - used less than 2 weeks before treatment with study or reference drug, or planned to use eltrombopag while the patient is participating in this study; - rituximab - used less than 14 weeks before treatment with study or reference drug, or planned to use rituximab while the patient is enrolled in this study; - cyclophosphamide, cyclosporine, vincristine, vinblastine and other drugs used to treat ITP not listed above and not included in the list of drugs approved for use during the study - use less than 8 weeks before the start of therapy with the study or reference drug or the use of any of these drugs is planned during the patient's participation in this study; - preparations of any hematopoietic growth factors - use less than 8 weeks before the start of therapy with an investigational or reference drug; - Influenza vaccines - less than 21 days prior to start of treatment with study or reference drug; - vaccines to prevent novel coronavirus disease (COVID-19) - completion of the vaccination program less than 21 days prior to the start of study or reference drug therapy; - other vaccines - less than 8 weeks prior to start of treatment with study or reference drug; 10. Splenectomy within 12 weeks prior to screening; 11. Participation in any clinical trials and/or use of unregistered drugs within 4 weeks prior to screening or 5 drug half-lives (whichever is greater); 12. Any other disease or condition that, in the opinion of the investigator, may preclude the patient from participating in the study.

Study Design


Related Conditions & MeSH terms


Intervention

Biological:
GNR-069
Once a week as a subcutaneous injection. The initial dose is 1 mcg/kg.
Nplate
Once a week as a subcutaneous injection. The initial dose is 1 mcg/kg.

Locations

Country Name City State
Russian Federation Municipal budgetary institution "Central City Hospital No. 7" Ekaterinburg
Russian Federation State Budgetary Institution of Healthcare Irkutsk awarded the "Sign of Honor" Order Regional Clinical Hospital Irkutsk Irkutsk Region
Russian Federation State Budgetary Health Institution of the Kaluga Region "Kaluga Regional Clinical Hospital" Kaluga Kaluga Region
Russian Federation State Autonomous Healthcare Institution "Kuzbass Clinical Hospital named after S.V. Belyaev" Kemerovo Kemerovo Region
Russian Federation Federal State Budgetary Institution "National Medical Research Center for Hematology" of the Ministry of Health of the Russian Federation Moscow
Russian Federation State budgetary health care institution of the city of Moscow "City Clinical Hospital named after V.V. Veresaev of the Department of Health of the City of Moscow" Moscow
Russian Federation State budgetary health care institution of the city of Moscow "Clinical Hospital named after S.P. Botkin" of the Department of Health of the city of Moscow Moscow
Russian Federation State Budgetary Health Institution of the Moscow Region "Moscow Regional Research Clinical Institute named after M.F. Vladimirsky" Moscow
Russian Federation State Budgetary Institution of Healthcare of the city of Moscow "Moscow Clinical Scientific and Practical Center named after A.S. Loginov" Department of Health of the city of Moscow. Moscow
Russian Federation Llc "Medis" Nizhny Novgorod Nizhny Novgorod Region
Russian Federation State budgetary institution of health care of the Nizhny Novgorod region "Nizhny Novgorod Regional Clinical Hospital named after N. A. Semashko" Nizhny Novgorod Nizhny Novgorod Region
Russian Federation Federal State Budgetary Educational Institution of Higher Education "Novosibirsk State Medical University" of the Ministry of Health of the Russian Federation Novosibirsk Novosibirsk Region
Russian Federation Federal State Budgetary Educational Institution of Higher Education "Rostov State Medical University" of the Ministry of Health of the Russian Federation Rostov-on-Don Rostov Region
Russian Federation Federal State Budgetary Institution "National Medical Research Center named after V.A. Almazov" of the Ministry of Health of the Russian Federation Saint Petersburg
Russian Federation Federal State Budgetary Educational Institution of Higher Education "Samara State Medical University" of the Ministry of Health of the Russian Federation Samara Samara Region
Russian Federation Federal State Budgetary Educational Institution of Higher Education "Saratov State Medical University named after V.I. Razumovsky" of the Ministry of Health of the Russian Federation Saratov Saratov Region
Russian Federation State Health Institution of the Tula Region "Tula Regional Clinical Hospital" Tula Tula Region
Russian Federation Federal State Budgetary Educational Institution of Higher Education "Bashkir State Medical University" of the Ministry of Health of the Russian Federation Ufa Republic Of Bashkortostan

Sponsors (1)

Lead Sponsor Collaborator
AO GENERIUM

Country where clinical trial is conducted

Russian Federation, 

Outcome

Type Measure Description Time frame Safety issue
Primary Proportion of patients achieving sustained response to treatment A sustained response to treatment is defined as the number of platelets = 50.0 x 109/L for at least 9 out of 12 consecutive visits during the treatment period with the study or reference drug. 26 weeks
Secondary Proportion of patients who achieve stable platelet count during treatment with investigational or reference drug Stable platelet count is defined as the number of platelets = 50.0 x 109/L for at least 4 consecutive weeks without dose adjustment. 26 weeks
Secondary Time from initiation of therapy with investigational or reference drug to reaching a stable platelet count 26 weeks
Secondary Number of cases of emergency therapy for severe hemorrhagic syndrome during the treatment period, starting from the second week of therapy with the investigational or reference drug 25 weeks
Secondary Number of clinically significant bleeding episodes during the treatment period, starting from the second week of therapy with investigational or reference drug Bleeding episode = Grade 2 according to CTCAE version 5.0 is considered clinically significant 26 weeks
Secondary Change in ITP-specific bleeding assessment tool (ITP-BAT) scores at last visit from baseline at screening 26 weeks
Secondary Proportion of patients with no/loss of response to treatment with investigational or reference drug 26 weeks
Secondary Proportion of patients receiving approved ITP prophylactic drugs (glucocorticosteroids, azathioprine, danazol) in this study at the time of randomization 26 weeks
See also
  Status Clinical Trial Phase
Completed NCT00451594 - High Dose Dexamethasone Vs. Conventional Dose Prednisolone in Adult ITP Phase 3
Withdrawn NCT01276561 - Single Incision Versus Standard Laparoscopic Splenectomy N/A
Completed NCT01713855 - Vaccine Response After Rituximab for Chronic, Severe Idiopathic Thrombocytopenic Purpura N/A
Recruiting NCT03465020 - Investigation on a Dynamic Cohort of Italian Patients With Active ITP
Completed NCT00603642 - P3 Study to Evaluate Efficacy and Safety of AMG 531 in Thrombocytopenic Japanese Subjects With Immune (Idiopathic) Thrombocytopenic Purpura Phase 3
Completed NCT01143038 - Interventional Study in Adults With Immune Thrombocytopenia Purpura (ITP) Receiving Romiplostim Phase 2
Not yet recruiting NCT04128358 - Triple Therapy in Patients With Idiopathic Thrombocytopenic Purpura : What is Behind? N/A
Completed NCT00128882 - Treatment of Idiopathic Thrombocytopenic Purpura (ITP) With Subcutaneously Administered Anti-D Phase 2
Completed NCT01525836 - rhTPO Combining Rituximab Versus Low-dose Rituximab in Management of ITP Phase 3
Completed NCT00888901 - Platelet Function in Idiopathic Thrombocytopenic Purpura (ITP) Patients With Eltrombopag Phase 4
Completed NCT00828750 - Clinical Evaluation of Eltrombopag in Chronic Idiopathic Thrombocytopenic Purpura (ITP) Phase 3
Completed NCT00625443 - Phase 2, Parallel Group, Rollover Study of AKR-501 in Patients With ChronicITP Who Completed 28 Days of Study Treatment in Protocol 501-CL-003 Phase 2
Completed NCT00475423 - A Study of MabThera (Rituximab) in Patients With Idiopathic Thrombocytopenic Purpura. Phase 2
Completed NCT00454857 - Retrospective & Prospective Observational Study of Patients With Immune (Idiopathic) Thrombocytopenic Purpura (ITP) N/A
Completed NCT00102323 - AMG 531 Treatment of Thrombocytopenic Subjects With Immune (Idiopathic) Thrombocytopenic Purpura (ITP) Refractory to Splenectomy Phase 3
Completed NCT05492409 - Study of the Safety and Immunogenicity of Long-term GNR-069 Therapy in ITP Patients Phase 3
Terminated NCT01433978 - A Phase 3, Multicenter, Randomized, Double-blind,Active-controlled, Parallel-group Trial With an Open-labelExtension Phase to Evaluate the Efficacy and Safety of OralE5501 Versus Eltrombopag, in Adults With Chronic ImmuneThrombocytopenia (Idiopathic Thrombocytopenic Purpura) Phase 3
Withdrawn NCT01443351 - Long-term Safety Study of Treatment With the Thrombopoietin Agonists Eltrombopag and Romiplostim in Patients With Immune Thrombocytopenia (ITP)
Completed NCT01520909 - Study of a New Medication for Childhood Chronic Immune Thrombocytopenia (ITP), a Blood Disorder of Low Platelet Counts That Can Lead to Bruising Easily, Bleeding Gums, and/or Bleeding Inside the Body. Phase 3
Not yet recruiting NCT06287567 - Lusutrombopag in the Treatment of Immune Thrombocytopenia (ITP) Phase 4